CR20240206A - Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19 - Google Patents
Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19Info
- Publication number
- CR20240206A CR20240206A CR20240206A CR20240206A CR20240206A CR 20240206 A CR20240206 A CR 20240206A CR 20240206 A CR20240206 A CR 20240206A CR 20240206 A CR20240206 A CR 20240206A CR 20240206 A CR20240206 A CR 20240206A
- Authority
- CR
- Costa Rica
- Prior art keywords
- subcutaneous administration
- binding
- cell engaging
- engaging antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/33—Antibodies; T-cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256056P | 2021-10-15 | 2021-10-15 | |
| US202163281992P | 2021-11-22 | 2021-11-22 | |
| PCT/EP2022/078638 WO2023062188A1 (en) | 2021-10-15 | 2022-10-14 | Subcutaneous administration of cd19-binding t cell engaging antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240206A true CR20240206A (es) | 2024-11-08 |
Family
ID=84360007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240206A CR20240206A (es) | 2021-10-15 | 2022-10-14 | Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250282864A1 (enExample) |
| EP (1) | EP4415829A1 (enExample) |
| JP (1) | JP2024537288A (enExample) |
| KR (1) | KR20240099263A (enExample) |
| AU (1) | AU2022364154A1 (enExample) |
| CA (1) | CA3235228A1 (enExample) |
| CL (1) | CL2024001075A1 (enExample) |
| CO (1) | CO2024006099A2 (enExample) |
| CR (1) | CR20240206A (enExample) |
| IL (1) | IL311714A (enExample) |
| JO (1) | JOP20240080A1 (enExample) |
| MX (1) | MX2024004617A (enExample) |
| PE (1) | PE20241619A1 (enExample) |
| TW (1) | TW202332695A (enExample) |
| UY (1) | UY39983A (enExample) |
| WO (1) | WO2023062188A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12698512B2 (en) | 2023-11-06 | 2026-08-04 | City Of Hope | Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers |
| AU2025227506A1 (en) | 2024-03-01 | 2026-08-13 | Amgen Research (Munich) Gmbh | Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| JP5798036B2 (ja) | 2008-11-07 | 2015-10-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 小児急性リンパ芽球性白血病の新規治療 |
| HUE043326T2 (hu) | 2008-11-07 | 2019-08-28 | Amgen Res Munich Gmbh | Akut limfoblasztos leukémia kezelése |
| WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| RU2651776C2 (ru) * | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
-
2022
- 2022-10-14 KR KR1020247015416A patent/KR20240099263A/ko active Pending
- 2022-10-14 CR CR20240206A patent/CR20240206A/es unknown
- 2022-10-14 UY UY0001039983A patent/UY39983A/es unknown
- 2022-10-14 JP JP2024521807A patent/JP2024537288A/ja active Pending
- 2022-10-14 WO PCT/EP2022/078638 patent/WO2023062188A1/en not_active Ceased
- 2022-10-14 IL IL311714A patent/IL311714A/en unknown
- 2022-10-14 AU AU2022364154A patent/AU2022364154A1/en active Pending
- 2022-10-14 PE PE2024000826A patent/PE20241619A1/es unknown
- 2022-10-14 US US18/704,120 patent/US20250282864A1/en active Pending
- 2022-10-14 MX MX2024004617A patent/MX2024004617A/es unknown
- 2022-10-14 CA CA3235228A patent/CA3235228A1/en active Pending
- 2022-10-14 TW TW111139062A patent/TW202332695A/zh unknown
- 2022-10-14 EP EP22805799.8A patent/EP4415829A1/en active Pending
-
2024
- 2024-04-07 JO JOJO/P/2024/0080A patent/JOP20240080A1/ar unknown
- 2024-04-11 CL CL2024001075A patent/CL2024001075A1/es unknown
- 2024-05-14 CO CONC2024/0006099A patent/CO2024006099A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4415829A1 (en) | 2024-08-21 |
| TW202332695A (zh) | 2023-08-16 |
| AU2022364154A1 (en) | 2024-04-04 |
| CA3235228A1 (en) | 2023-04-20 |
| WO2023062188A1 (en) | 2023-04-20 |
| IL311714A (en) | 2024-05-01 |
| MX2024004617A (es) | 2024-06-19 |
| CO2024006099A2 (es) | 2024-05-20 |
| KR20240099263A (ko) | 2024-06-28 |
| JOP20240080A1 (ar) | 2024-04-07 |
| US20250282864A1 (en) | 2025-09-11 |
| JP2024537288A (ja) | 2024-10-10 |
| CL2024001075A1 (es) | 2024-08-09 |
| UY39983A (es) | 2023-04-14 |
| PE20241619A1 (es) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001075A1 (es) | Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19 | |
| EA201890028A1 (ru) | Антитело, связывающее cd3 человека | |
| MX2023014643A (es) | Un grupo de anticuerpos monoclonales b7h3 y uso medico del mismo. | |
| CL2024000802A1 (es) | Anticuerpos que se fijan a gprc5d | |
| CO2020008940A2 (es) | Anticuerpos de unión a gprc5d | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| BR112019008426A2 (pt) | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| AR122658A1 (es) | Anticuerpos que se unen a cd3 | |
| CR20210373A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| AR114001A1 (es) | Anticuerpos que se unen a hla- a2 / wt1 | |
| CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| MX2018013525A (es) | Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| JOP20190103B1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| ES2721378T3 (es) | Anticuerpos anti-TLR4 y métodos de uso de los mismos | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| EA201992431A1 (ru) | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса | |
| CR20240204A (es) | Complejo polipeptídico activable | |
| MX2018001095A (es) | Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico. | |
| MX2025012459A (es) | Métodos para tratar el mieloma múltiple | |
| BR112021011595A2 (pt) | Proteína biespecífica |